News Releases

GDC-0032, a potent, next-generation PI3 kinase inhibitor, demonstrated early signs of efficacy for patients with cancers driven by mutations in the PI3 kinase alpha gene, according to first in-human results presented at the AACR Annual Meeting 2013.

Next-generation PI3 Kinase Inhibitor Demonstrated Early Efficacy, Safety

07/Apr/2013

GDC-0032, a potent, next-generation PI3 kinase inhibitor, demonstrated early signs of efficacy for patients with cancers driven by mutations in the PI3 kinase alpha gene, according to first in-human results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

“We’ve shown that this novel agent is well tolerated,” said Dejan Juric, M.D., lead investigator of the study at the Termeer Center for Targeted Therapies at Massachusetts General Hospital in Boston. “We’ve shown that the safety profile is favorable and that the side effects are predictable. Early results show that the drug has very promising activity, particularly in tumors that have activating mutations in PI3 kinase alpha.”

Link to full AACR release.

patient

U.S. News and World Report Best Hospitals 2014-2015

U.S. News & World Report ranks Mass General #1 in New England and #2 in the nation based on our quality of care, patient safety and reputation in 16 clinical specialties.

Search the Mass General news archive

Search the archive for previously published news articles, press releases and publications.

View all departments

Departments and Centers at Mass General have a reputation for excellence in patient care. View a list of all departments.